The power of one: Introducing a novel one-day workflow for simultaneous high-sensitivity analysis of DNA and RNA

Cancer is a highly complex disease and understanding the various alterations that together determine mechanisms of disease onset, progression, recurrence and response to treatment is not trivial. Currently, multimodal approaches are used to explore biomarker status using DNA variant profiling and RNA fusion information. Though the information derived enables a better understanding of the various mechanisms in play, having to perform separate workflows increases the overall cost of the study due to the number of instruments, reagents, consumables and resources needed. Furthermore, samples, especially those derived from tissues, are often of limited quantity and quality. Therefore, streamlined workflows optimized with low sample-input requirements are preferred to ensure the retention of samples for further downstream studies.

In this webinar, we present an innovative approach to biomarker analysis, enabling simultaneous extraction and NGS-based interrogation of DNA and RNA from a single sample in just one day. This approach not only reduces hands-on and overall turn-around time for combined DNA and RNA profiling but, more importantly, provides critical DNA and RNA information from a single sample, enabling confident assessment of allelic expression of variants for a complete profile of the underlying molecular signatures related to disease.

Raed Samara, Ph.D, Senior Global Product Manager, QIAGEN

Raed Samara
Raed Samara is Global Product Manager for next-generation sequencing technologies at QIAGEN. Prior to joining QIAGEN, he was a postdoctoral fellow at the National Cancer Institute conducting research in the field of cancer immunology with emphasis on identifying strategies to boost the efficacy of cancer vaccines. He received his Ph.D. degree from Georgetown University in tumor biology.

Jonathan Shaffer, Ph.D.

Jonathan M. Shaffer
Dr. Shaffer joined QIAGEN in 2009 and has since worked with various technology development groups, the most recent being miRNA technologies. He received his Ph.D. in biochemistry and molecular genetics from the University of Pittsburgh School of Medicine in 2008 where his research focused on determining the mechanisms that regulate non-receptor tyrosine kinase expression and activity. Dr. Shaffer did his postdoctoral training at SABiosciences Corporation, now part of QIAGEN. Currently, Dr. Shaffer is a Senior Scientist in Product Development at QIAGEN.